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Abstract 
Background: LADA is probably the most prevalent form of autoimmune diabetes. Nevertheless, there are few 
data about cardiovascular disease in this group of patients. The aim of this study was to investigate the frequency of 
carotid atherosclerotic plaques in patients with LADA as compared with patients with classic type 1 diabetes and type 
2 diabetes.
Methods: Patients with LADA were matched for age and gender in different proportions to patients with type 2 
diabetes, and classic type 1 diabetes. None of the patients had clinical cardiovascular disease. All subjects underwent 
B‑mode carotid ultrasound to detect atheroma plaques. Demographics were obtained from all subjects.
Results: We included 71 patients with LADA, 191 patients with type 2 diabetes and 116 patients with type 1 diabe‑
tes. Carotid atherosclerosis was more frequent in patients with LADA compared with type 2 diabetes (73.2% vs. 56.9%, 
P = 0.0018) and classic type 1 diabetes (57.1%, P = 0.026); these changes occurred despite healthier macrovascular 
risk profiles in the former. Age (P < 0.001), smoking (P = 0.003) and hypertension (P = 0.019) were independently 
associated with carotid atherosclerosis. Multiple plaques were also more frequent in patients with LADA as compared 
with classic type 1 diabetes and type 2 diabetes (45.1% and 33.6% vs. 27.2%, respectively, P = 0.022). The frequency of 
carotid plaques increased with increasing diabetes duration in LADA patients compared with type 2 diabetes (85.7% 
vs. 58.8%, inverse OR 5.72 [1.5–21.8]; P = 0.009).
Conclusions: LADA patients do not present with less carotid atherosclerosis than patients with type 1 and type 2 
diabetes. Their macrovascular risk occurs despite a healthier macrovascular risk profile than those patients with type 2 
diabetes.
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Background
Macrovascular disease is the leading cause of morbidity 
and mortality in patients with both type 1 diabetes and 
type 2 diabetes [1]. Latent autoimmune diabetes of the 
adults (LADA), that is patients with adult-onset autoim-
mune diabetes who do not initially require insulin, rep-
resent 4–14% of subjects previously diagnosed with type 
2 diabetes [2]. LADA can be estimated to have a higher 
prevalence than classic type 1 diabetes in both children 
and adults. Notwithstanding its clinical relevance, data 
about cardiovascular events and mortality in patients 
with LADA are limited. It could be anticipated that 
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patients with LADA would be less likely to develop mac-
rovascular disease than patients with type 2 diabetes, as 
they have a reduced risk of metabolic syndrome [3–5]. 
However, most studies to date, despite their limited size, 
population heterogeneity and variable disease duration, 
have failed to show such a reduced risk, and indeed many 
find an increased risk [6–9].
Preclinical atherosclerosis can be detected and quan-
tified non-invasively by carotid ultrasound, which is 
a strong predictor of cardiovascular events [10–16]. 
Although there is still controversy in this field, estab-
lished carotid atherosclerosis (carotid plaques), detected 
by ultrasound imaging, improves risk stratification when 
added to traditional risk factors. Indeed, individuals with 
carotid plaques are considered a very-high risk category 
according to the most recent guidelines, and carotid 
artery plaque assessment using ultrasonography may be 
considered to be a valid risk modifier in cardiovascular 
prediction [17–19]. Patients with diabetes mellitus are at 
high risk of cardiovascular events; therefore, the added 
potential of carotid plaque detection in risk assessment 
would be different from those cases without diabetes 
[20–22]. However, primary prevention targets are often 
not reached in patients with diabetes, and carotid plaque 
detection could focus more intensive preventive strate-
gies in these cases, especially in those patients without 
known organ damage or important associated cardiovas-
cular risk factors [18, 19, 23].
The current study was initially designed to assess the 
difference in preclinical carotid plaque burden in patients 
with LADA, as compared to type 2 diabetes. After the 
results of the initial study, we extended the comparison 
to age and gender matched patients with classic onset 
type 1 diabetes.
Methods
This was a cross-sectional study to evaluate carotid ath-
erosclerotic disease in patients with LADA in compari-
son with patients with type 2 diabetes and classic onset 
type 1 diabetes.
Study subjects
All adult patients attending local diabetes outpa-
tient clinics in the province of Lleida, Spain, who were 
screened for diabetes-associated autoantibodies and 
defined as LADA if they had diabetes diagnosed over 
30  years of age, with positive glutamic acid decarboxy-
lase (GAD) antibodies and without need of insulin treat-
ment in the first 6 months after diagnosis [24]. From this 
cohort of 80 LADA patients, we invited all the patients 
that fulfilled the inclusion criteria (n  =  71, accept-
ance rate: 100%): absence of clinical cardiovascular dis-
ease and without established diabetic nephropathy 
[urine albumin-to-creatinine ratio (UACR)  <  300  mg/g 
and estimated (MDRD4) glomerular filtration rate 
(eGFR) > 60 ml/min/1.73 m2].
Age- and sex-matched subjects with type 2 diabetes 
were randomly selected to a 3:1 proportion and for clas-
sic onset type 1 diabetes on a 2:1 proportion from the 
same local cohort using the same cardiovascular and 
renal inclusion criteria. All patients selected with type 2 
diabetes were negative for GAD antibodies.
The absence of clinical macrovascular disease in all 
subjects was confirmed by clinical assessment and review 
of patients’ medical records to verify absence of heart 
failure, cerebrovascular disease, coronary heart dis-
ease, or peripheral arterial disease (all of them clinically 
assessed, including any form of diabetic foot disease).
All the participants signed an informed consent form 
and the Ethics Committee of both participant centers 
approved the study.
Clinical assessment
For each subject, age, sex, weight, height, body mass 
index and waist circumference were measured by stand-
ardized methods. Blood pressure (mean of 2 measure-
ments 5 min apart) was measured using a blood pressure 
monitor (HEM-7001E, Omron, Spain) after 10 min in the 
seated position. Patients were specifically interviewed 
about the treatment of diabetes and smoking habit. For-
mer smokers were those who had quit at least for 1 year 
before enrollment. A patient was arbitrarily considered to 
have previous hypertension or dyslipidemia if she/he was 
taking medication for the given condition.
Fasting blood and urine samples were collected and 
analyzed locally, using standardized assays to meas-
ure glucose, glycosylated haemoglobin, the lipid profile 
[including high-density lipoprotein (HDL) cholesterol, 
low-density lipoprotein (LDL) cholesterol and triglycer-
ides] creatinine and the albumin-to-creatinine ratio. Glo-
merular filtration rate was estimated by the modification 
of diet in renal disease formula (MDRD4). GAD antibod-
ies were measured with a commercially available ELISA 
kit (DRG Diagnostic, Marburg, Germany), as previously 
described [25]. Optimal cut-off value for positivity was 
set at 5 U/ml. The assay showed good performance when 
tested in the Diabetes Antibody Standardization Program 
(DASP) Workshops. In DASP 2007, sensitivities and spe-
cificities for GAD antibodies were 94 and 97% and in 
DASP 2009 were 82 and 95%, respectively.
Carotid ultrasound imaging
All the study participants underwent the same carotid 
ultrasound protocol. Carotid ultrasound imaging was 
performed using a high resolution B-mode ultra-
sound (Sequoia 512, Siemens, North Rhine-Westphalia, 
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Germany) equipped with a 15-Mhz linear array probe. A 
standardized imaging protocol was performed to evalu-
ate intima-media-adventitia thickness (IMT) as has been 
described before [26]. The analysis of the presence of 
atheromatous plaques was performed indistinctly by two 
readers in a non-blinded fashion. Plaques were identi-
fied using B-mode and color Doppler examinations in 
both the longitudinal and transverse planes to consider 
circumferential asymmetry. Plaques were defined accord-
ing to the Mannheim consensus [27]. We examined bilat-
eral carotid arteries (common, bifurcation and internal) 
to evaluate the presence of plaques. Subclinical carotid 
atherosclerosis was defined as the presence of at least 
one plaque in any of the carotid territories explored. The 
presence of multiple plaques, defined by the presence of 
plaques in more than one of the explored territories, was 
considered to reflect more severe atherosclerotic disease 
[28, 29].
Sample size
For the comparison of LADA and classic type 1 diabetes 
with type 2 diabetes, we hypothesized a carotid plaque 
frequency of 50% for the former two and 70%, for the 
latter; the latter was based on the known frequency in 
our local cohort, and the former on a presumed reduced 
frequency. We calculated that with LADA (n = 62) and 
type 2 diabetes (n = 186) we would have 80% power, at 
P  <  0.05 to detect differences. Using the 2:1 proportion 
for classic type 1 diabetes we calculated a minimum sam-
ple size of 104 subjects (80% power, P < 0.05).
Statistical analysis
A comparison of the characteristics between groups was 
performed expressing the quantitative variables as mean 
and standard deviation, and qualitative variables as fre-
quencies and percentages. The statistical significance of 
differences between groups was assessed using the Chi 
square test for comparison of proportions, and analysis 
of variance (ANOVA) for comparison of means. Multiple 
pairwise comparisons were performed using Bonferroni 
correction. To assess whether the frequency of plaque 
and/or multiple plaque was associated with the type of 
diabetes the crude Odds Ratio was calculated and sub-
sequently adjusted with the respective confidence inter-
vals at 95%. The adjustment variables, besides the type 
of diabetes, were duration of diabetes, age, sex, smoking, 
hypertension, dyslipidemia and retinopathy at the time of 
inclusion. Age and duration of diabetes were categorized 
according to tertiles, and adjusted models were intro-
duced by functions smoothing splines, with a focus on 
automatic smoothing parameter selection. The adjusted 
ORs were estimated using generalized additive models 
with logit link with package “gam” [30, 31] from R 3.2.1 
statistical software [32]. The goodness of fit of the models 
was assessed with the Hosmer–Lemeshow test. P values 
less than 0.05 were considered statistically significant.
Results
We recruited 71 patients with LADA, 191 patients with 
type 2 diabetes and 116 patients with type 1 diabetes. The 
clinical characteristics of the study groups are shown in 
Table  1. Patients with LADA, classic type 1, and type 2 
diabetes were similar in age, gender distribution, cur-
rent smoking status, use of antihypertensive drugs, and 
HbA1c concentrations. As patients were matched by 
age, the diabetes duration was longer in patients with 
type 1 diabetes than in patients with LADA, but also, 
in the latter duration was longer than in type 2 diabetes 
(23.7 ± 12.4, 13.2 ± 9.7 and 8.7 ± 7.9 years, respectively, 
P < 0.001). While the prevalence of diabetic retinopathy, 
as expected given the longer disease duration, was higher 
in type 1 diabetes than in LADA and type 2 diabetes, the 
frequency of microalbuminuria was similar. About half 
the patients with LADA were treated with metformin, 
and the majority were receiving insulin. Patients with 
type 2 diabetes, as expected, exhibited a more adverse 
lipid profile and anthropometric measures than the other 
two cohorts, though fewer were on statin treatment.
For carotid ultrasound findings: mean carotid IMT 
was lower in patients with type 1 diabetes compared to 
both LADA and type 2 diabetes (Table  1). As shown in 
Fig.  1 subclinical carotid atherosclerosis (presence of 
atherosclerotic plaques) was more frequent in patients 
with LADA than in patients with type 1 diabetes and 
type 2 diabetes [73.2% vs. 57.1% (P =  0.026) and 56.9% 
(P  =  0.018), respectively]. Multiple plaques were also 
more frequent in patients with LADA than in type 1 dia-
betes and type 2 diabetes [45.1% vs. 33.6% (P =  0.077), 
and 27.2% (P = 0.019), respectively] (Fig. 1).
Carotid plaques were also related to older age, longer 
diabetes duration, hypertension, retinopathy and dyslipi-
demia (Table 2).
A multivariate logistic regression model including age, 
diabetes duration, gender, type of diabetes, retinopa-
thy, hypertension, smoking and dyslipidemia (Table  3) 
revealed that age, but not gender, type of diabetes, and 
the presence of hypertension and smoking habit were 
associated with carotid atherosclerosis. The adjusted 
inverse OR for the presence of carotid plaques in patients 
with LADA as compared with those with type 1 and type 
2 diabetes was 2.44 [(1.65–3.6); P  =  0.0225] and 2.06 
[(1.47–2.9); P = 0.0334], respectively.
To explore the impact of disease duration on carotid 
plaque frequency in patients with LADA, we limited 
the analysis to patients with LADA and type 2 diabetes, 
as few patients with type 1 diabetes had a short diabetes 
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duration. We divided patients with LADA and type 2 dia-
betes into age-adjusted tertiles of disease duration: ≤5, 
6–11, ≥12 years. Table 4 shows the results of this analy-
sis; within 5 years of diabetes duration the prevalence of 
carotid plaques was lower, though not significantly so, in 
patients with LADA than in those with type 2 diabetes 
[26.7% vs. 54.8%, inverse OR 0.38 (0.11–1.39); P = 0.137]. 
However, with increasing diabetes duration the fre-
quency of carotid atherosclerotic plaques increased 
in patients with LADA, but not in patients with type 2 
diabetes [81.8% vs. 50%, inverse OR 5.72 (1.5–21.8); 
P = 0.009].
Discussion
In this study, we unexpectedly found an increased fre-
quency of subclinical carotid atherosclerosis in patients 
with LADA, as compared to subjects with classic type 
1 diabetes and type 2 diabetes. That excess frequency of 
carotid disease was also evident when assessing multi-
ple plaques in LADA compared with the other cohorts. 
We did not find the same results for cIMT as for carotid 
plaque, potentially due to the high variability and low 
intra-individual reproducibility of the former measure-
ment [33]. Moreover, the pathophysiology underlying 
the development of carotid plaque and cIMT is distinct 
and the evidence regarding the value of cIMT in cardio-
vascular risk prediction is contradictory and of debatable 
value [34–36]. Most recent clinical guidelines on cardio-
vascular risk do not recommend carotid IMT for individ-
ual risk prediction [18, 37]. In contrast, the presence of 
carotid plaques has been shown to be a good predictor of 
future cardiac events [15, 18].
The high frequency of carotid plaques, despite the 
increased use of statins in LADA cases, remained after 
adjusting for the main cardiovascular risk factors, includ-
ing diabetes duration. The current cross-sectional study 
does not allow for the identification of potential causes of 
our unexpected finding of higher atherosclerotic burden 
in LADA, even though patients with type 2 diabetes tend 
to exhibit, as in other studies, a worse cardiovascular risk 
profile including higher blood pressure, more obesity and 
an adverse lipid profile. In both the Freemantle Study [38] 
Table 1 Characteristics of study subjects Table 1
Values are expressed as the mean ± SD or percentages
LADA latent autoimmune diabetes in adults, BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, HbA1c glycosylated haemoglobin
a  Type 2 diabetes different from LADA and type 1 diabetes
b  Type 2 diabetes different from LADA
c  Type 1 diabetes different from LADA and type 2 diabetes
Variables Type 1 diabetes (n = 116) LADA (n = 71) Type 2 diabetes (n = 191) P value
Age (years) 56.5 ± 10.8 58.3 ± 11.6 58.3 ± 10.5 0.321
Male n (%) 52 (44.8) 37 (52.1) 105 (55) 0.224
BMI (kg/m2) 26.5 ± 3.9 27.4 ± 5 31.3 ± 5.3 <0.001a
Waist (cm) 91.6 ± 13.3 96.3 ± 14 104.8 ± 11.7 <0.001
Diabetes duration (years) 23.7 ± 12.4 13.2 ± 9.7 8.7 ± 7.9 <0.001
Smoking (current/past/never) n (%) 21 (18.1)/33 (28.4)/62 (53.4) 17 (23.9)/22 (31)/32 (45.4) 41 (21.5)/66 (34.6)/83 (43.5) 0.647
Anti‑hypertensive treatment n (%) 54 (46.6) 37 (52.1) 98 (51.3) 0.667
Statin treatment n (%) 73 (62.9) 42 (59.2) 71 (37. 2) <0.001a
Antiplatelet agents n (%) 50 (43.1) 40 (56.3) 59 (30.9) 0.002b
Metformin treatment n (%) 0 31 (43.7) 138 (72.3) <0.001
Insulin treatment n (%) 100 63 (88.7) 37 (19.4) <0.001
Fasting glycemia (mg/dl) 170.9 ± 79.1 143.8 ± 53.4 151.7 ± 52.6 0.006c
HbA1c (%) 7.7 ± 1 7.7 ± 1.1 7.4 ± 1.3 0.07
HbA1c (mmol/mol) 60.6 ± 12.5 61 ± 11.4 57.3 ± 18.6 0.07
Total cholesterol (mg/dl) 184.9 ± 29.8 178.9 ± 37.8 185.6 ± 35.3 0.357
LDL‑cholesterol (mg/dl) 102.6 ± 25.4 102 ± 24.8 110.6 ± 29.4 0.015a
HDL‑cholesterol (mg/dl) 65.9 ± 14.6 61.5 ± 18.2 48.4 ± 12.1 <0.001a
Triglycerides (mg/dl) 79.9 ± 36.4 100.5 ± 72.9 141.3 ± 78.7 <0.001a
Diabetic retinopathy n (%) 52 (44.8) 13 (18.3) 36 (18.8) <0.001c
Microalbuminuria > 30 mg/g creatinine 10 (8.6) 7 (9.9) 12 (6.3) 0.563
Urinary albumin:creatinine ratio (mg/g) 12.2 ± 29.8 20.1 ± 69.6 14.5 ± 32.9 0.451
Mean IMT 0.750 ± 0.109 0.775 ± 0.147 0.793 ± 0.135 0.047c
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and the Collaborative Atorvastatin Study [7], patients 
designated LADA had comparable cardiovascular disease 
as the patients with type 2 diabetes; while in the Botnia 
study [6] after 13 years of diabetes 56% of LADA patients 
had ischemic heart disease and 5% had had cerebrovas-
cular events. To date, only one other study has assessed 
the frequency of carotid atherosclerosis in patients with 
LADA and type 2 diabetes [8], and none have assessed 
that frequency in the three cohorts we assessed. That Chi-
nese study was retrospective and not designed to answer 
the question we posed here, but they did find a compa-
rable frequency of carotid atherosclerosis compared with 
type 2 diabetes patients. Taken together, these studies 
indicate that patients with adult-onset diabetes, irrespec-
tive of the cause of the diabetes, are at risk of carotid and 
coronary atherosclerosis. It is difficult to understand why 
this should be, given that autoimmune diabetes cases are 
less likely to have the metabolic syndrome and related 
features [7]. Two possibilities suggest themselves. First, 
the time of onset of autoimmune diabetes antedates the 
disease by months, even years, and it remains possible 
that LADA patients have had low-grade disease many 
years before clinical presentation, as can be the case with 
type 2 diabetes. However, the duration of LADA pre-dis-
ease is unknown both in this study and in general, while 
the risk of atherosclerosis in these cases was increased 
with increasing diabetes duration post-diagnosis. Second, 
patients with LADA are not well managed and are con-
sistently shown to have higher HbA1c levels than compa-
rable cohorts of patients with type 2 diabetes [4, 39–41]. 
Higher HbA1c has been found to be associated with 
Fig. 1 Carotid atherosclerosis in patients with LADA, type 1 and 
type 2 diabetes. The percentage of patients with carotid plaques was 
significantly higher in the LADA group (73.2%) than in the group of 
patients with type 1 diabetes (57.1%, P = 0.026) and type 2 diabetes 
(56.9%, P = 0.018). The difference was mainly due to the percentage 
of patients with multiple plaques, which was higher in LADA (45.1%), 
than in type 1 diabetes (33.6%), P = 0.077 and type 2 diabetes 
(27.2%), P = 0.019. LADA latent autoimmune diabetes in adults
Table 2 Univariate analysis for the presence of carotid ath-
erosclerotic plaques
LADA latent autoimmune diabetes in adults
Odds ratio (95% confidence 
interval)
P value
Diabetes
 LADA 1
 Type 1 diabetes 0.482 (0.254–0.916) 0.026
 Type 2 diabetes 0.486 (0.267–0.884) 0.018
Diabetic retinopathy 1.954 (1.195–3.196) 0.008
Male sex 1.275 (0.844–1.926) 0.248
Dyslipidemia 1.808 (1.192–2.747) 0.005
Hypertension 2.639 (1.721–4.032) <0.001
Smoker/former smoker 1.464 (0.868–2.469) 0.152
Diabetes duration (tertiles)
 ≤5 years 1
 6–11 years 1.360 (0.779–2.375) 0.279
 ≥12 years 1.875 (1.140–3.084) 0.013
Age (tertiles)
 ≤52 years 1
 53–63 years 2.267 (1.371–3.748) <0.001
 ≥64 years 3.707 (2.177–6.313) <0.001
Table 3 Adjusted Odds ratio for  the presence of  carotid 
atherosclerotic plaques
Odds ratio was adjusted by age and diabetes duration using a generalized 
additive model
LADA latent autoimmune diabetes in adults
Adjusted odds ratio  
(95% confidence interval)
P value
Diabetes
 LADA 1
 Type 1 diabetes 0.410 (0.278–0.606) 0.0225
 Type 2 diabetes 0.485 (0.345–0.682) 0.0334
Diabetic retinopathy 1.258 (0.910–1.741) 0.4790
Female sex 0.764 (0.603–0.967) 0.2530
Dyslipidemia 1.252 (0.980–1.599) 0.3587
Hypertension 1.773 (1.389–2.264) 0.0189
Smoker/former smoker 2.471 (1.824–3.349) 0.0029
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higher coronary and carotid atherosclerotic burden in 
non-diabetic patients [42]. Additionally, deranged glyce-
mic control has been independently related to coronary 
heart disease in both LADA patients [6], and diabetes 
patients in general [40, 43]. Higher HbA1c concentra-
tions have also been related to cardiovascular disease 
in the non-diabetic population in prospective studies, 
including the Norfolk cohort of European Prospective 
Investigation into Cancer and Nutrition study [44] and 
The Copenhagen City Heart Study [45].
In subjects with diabetes, other potential different 
pathophysiological mechanisms may be involved in the 
atherosclerotic process. First, advanced glycation end 
products (AGEs) which are increased in diabetes are pro-
oxidants that induce oxidative stress and are thought to 
play a major role in atherosclerosis [46, 47]. Although 
diet is the principal source of AGEs, their concentra-
tions rise with increasing blood glucose. An increased 
level of advanced AGEs has been associated with cardio-
vascular disease in type 1 diabetes [48] and type 2 dia-
betes [49]; no such data is available in LADA. Secondly, 
patients with systemic autoimmune diseases, such as 
rheumatoid arthritis or systemic lupus erythematosus, 
have an increased risk of atherosclerosis, with both cel-
lular and humoral components of the immune system 
involved in its pathogenesis and some shared genetic 
risk [50], although the precise mechanisms underlying 
the high cardiovascular risk in these patients is unclear 
[51]. It is well known that chronic inflammation plays an 
important role in atherogenesis [52, 53], and inflamma-
tory markers associated with macrovascular disease are 
elevated both in patients with type 1 diabetes and type 
2 diabetes [54, 55]. Moreover, poor glycemic control and 
hypoglycaemic episodes are related to pro-inflammatory 
status [56, 57], and may be additional contributing fac-
tors in atherosclerosis in patients with autoimmune dia-
betes [58]. Unfortunately, in the current study we did not 
determine any markers of chronic inflammation in the 
LADA patients, though we have previously demonstrated 
such changes in LADA patients [59].
Nevertheless, this study has some weaknesses. First of 
all, the size of the populations studied is relatively small, 
and some important information is missing, notably the 
familial history of premature cardiovascular disease. 
While we found no differences in HbA1c between the 
three diabetes groups, this is a cross-sectional study, and 
the relationship between glycemic control and athero-
sclerosis can only be answered with a prospective design. 
The situation is made more complex because most of 
the patients with LADA in this study had already been 
referred to specialized care, usually because of poor gly-
cemic control. The specialized diabetes care of all the 
patients with type 1 diabetes and most of the patients 
with LADA may explain the increased use of statins and 
antiplatelet agents in these groups compared to that of 
patients with type 2 diabetes, since the latter are usually 
under general practitioner’s care. Since LADA patients 
were recruited from a specialty-based cohort our results 
may show a bias; however, this group of LADA subjects is 
likely representative of LADA patients in general in Spain.
Nevertheless, despite its limitations, our study has 
the strength of comparing for the first time these three 
groups of diabetes, which come from a homogeneous 
population. While we use the term LADA throughout 
the text for clarity, we would prefer that LADA is called 
adult-onset autoimmune diabetes since there is no firm 
evidence that LADA can be categorically distinguished 
from type 1 (autoimmune) diabetes.
Conclusions
Our results indicate that the frequency of preclini-
cal carotid atherosclerosis in patients with adult-
onset initially non-insulin requiring autoimmune 
diabetes, also called LADA, is comparable, even greater, 
than in adults of similar age with classic type 1 diabe-
tes and type 2 diabetes. Our data should be confirmed 
Table 4 Age-adjusted frequency of carotid atherosclerotic plaques in patients with LADA and type 2 diabetes, divided 
by tertiles of disease duration
LADA latent autoimmune diabetes in adults
Diabetes duration N Carotid plaque (%) Inverse OR (95% confidence interval) P value
≤5 years
 Type 2 diabetes 84 54.8 0.137
 LADA 15 26.7 0.38 (0.11–1.39)
6–11 years
 Type 2 diabetes 60 50 0.009
 LADA 22 81.8 5.72 (1.5–21.8)
≥12 years
 Type 2 diabetes 47 70.2 0.038
 LADA 34 88.2 4.19 (1.06–16.6)
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in both cross-sectional and prospective studies in other 
populations. However, the results draw attention to the 
importance of macrovascular disease in patients with 
diabetes, irrespective of the cause of the disease, and 
emphasize the potential value of rigorous treatment of 
macrovascular risk factors even in patients with autoim-
mune diabetes.
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